Author

G G Schwartz

Institution: University of Colorado Anschutz

Observed institution: University of Colorado Anschutz

OpenAlex ID: A5159730660

Lipoprotein(a), smoking, and diabetes are additive, but not interactive risk factors for major adverse cardiovascular events after acute coronary syndrome: An analysis of the ODYSSEY OUTCOMES trial

2026 · G G Schwartz, M Szarek, et al. · European Heart Journal

Design and baseline data of AZURE-HeFH, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with heterozygous familial hypercholesterolaemia

2026 · E S Stroes, R S Rosenson, et al. · European Heart Journal

Association of lipoprotein(a) levels with risk of serious bleeding : findings from the ODYSSEY OUTCOMES trial

2026 · P Steg, M S Szarek, et al. · European Heart Journal

Variability in lipoprotein(a) measurements in ODYSSEY OUTCOMES: is one-and-done testing sufficient?

2026 · M Szarek, P G Steg, et al. · European Heart Journal

Design and baseline data of AZURE-LDL, a phase 3 study assessing the effect of the oral PCSK9 inhibitor laroprovstat on LDL cholesterol in patients with, or at risk for, ASCVD

2026 · E S Stroes, M Koren, et al. · European Heart Journal

Works count: 5

Citation count:

H-index:

I10-index: